Table S1 Characteristics of included articles

Study ID	Study location	Study type	Time	Sample size	Sex (%,man)	Age (year)
Luo 2020 (11)	Wuhan	Case series	2020/01/30–2020/02/25	403	193 (47.9)	56.0 (39.0, 68.0)**
Young 2020 (20)	Singapore	Cohort study	2020/01/22–2020/03/06	100	56 (56.0)	46.0*
Ng 2020 (21)	Singapore	Case series	2020/01/02–2020/02/29	100	60 (60.0)	42.5*
Jung 2020 (22)	South Korea	Case series	2020/02/01–2020/04/01	14	6 (42.9)	63.5±14.5*
Hong 2020 (23)	South Korea	Case series	To 2020/03/29	98	38 (38.8)	55.4±17.1*
Husain 2020 (24)	The United States	Case series	2020/03/13–2020/04/06	41	30 (73.2)	49.0 (41.0, 63.0)**
Cummings 2020 (25)	The United States	Cohort study	2020/03/02–2020/04/01	257	171 (66.5)	62.0 (51.0, 72.0)**
Dreher 2020 (26)	Germany	Case series	2020/02/01–2020/03/01	50	33 (66.0)	65.0 (58.0, 76.0)**
Imai 2020 (27)	Japan	Case series	2020/02/11–2020/03/31	112	64 (57.1)	67.0 (45.0, 74.0)**
Mahévas 2020 (28)	French	Case series	2020/03/12–2020/03/31	173	125 (72.3)	60.0 (52.0, 68.0)**
Gao 2020 (58)	Shanxi	Case series	2020/01/21–2020/02/18	40	19 (47.5)	41.0±16.4*
Fu 2020 (59)	Chongqing	Case series	2020/01/21–2020/02/25	51	27 (52.9)	60.9±14.9*
Liu 2020 (31)	Hunan	Case series	2020/01/21–2020/02/13	697	–	–
Liu 2020 (60)	Wuhan	Case series	To 2020/03/11	47	32 (68.1)	–
Huang 2020 (61)	Wuhan	Case series	2019/12/29–2020/02/27	305	167 (54.8)	54.5±14.4*
Liu 2020 (40)	Guangdong	Case series	2020/01/01–2020/03/31	73	37 (0.5)	52.2±15.6*
Liu 2020 (62)	Henan	Case series	To 2020/02/08	15	10 (66.7)	46.5*
Han 2020 (44)	Wuhan	Case series	2020/01/12–2020/02/16	120	63 (52.5)	53.0±14.0*
Yu 2020 (63)	Beijing	Case series	2020/01/21–2020/02/25	50	32 (64.0)	40.0±18.4*
Xia 2020 (64)	Hunan	Case series	From 2020/01/16	33	19 (57.6)	39.0**
Chen 2020 (41)	Hainan	Case series	2020/01/22–2020/03/04	168	81 (48.2)	51.0**
Ye 2020 (33)	Wuhan	Case series	2020/02/15–2020/02/25	55	29 (52.7)	59±13.1*
Yang 2020 (65)	Jiangsu	Case series	–	57	29 (50.9)	37.0**
Li 2020 (66)	Henan	Case series	2020/01/21–2020/02/24	256	159 (62.1)	–
Cao 2020 (67)	Chongqing	Case series	2020/01/24–2020/02/23	223	105 (47.2)	46.5±16.1*
Yuan 2020 (46)	Chongqing	Case series	2020/01/24–2020/02/23	223	106 (47.5)	46.5±16.1*
Zeng 2020 (68)	Chongqing	Case series	2020/01/21–2020/02/25	353	193 (54.7)	46.3*
Chen 2020 (69)	Fujian	Case series	–	111	57 (51.4)	49.5**
Hu 2020 (70)	Hunan	Case series	2020/01/01–2020/02/08	852	460 (51.8)	44.0**
Zhang 2020 (71)	Hubei	Case series	2020/02/06–2020/03/07	120	73 (60.8)	–
Yang 2020 (72)	Hubei	Case series	2020/01/30–2020/03/21	40	22 (55.0)	51.2*
An 2020 (73)	Wuhan	Case series	2020/01/24–2020/02/19	110	44 (40.0)	–
Liu 2020 (74)	Shanxi	Case series	2020/01/23–2020/03/02	245	131 (53.5)	46.2*
Li 2020 (29)	Liaoning	Case series	2020/01/26–2020/02/29	26	14 (53.9)	43.9±11.9*
Shi 2020 (75)	Zhejiang	Case series	2020/01/17–2020/01/29	65	37 (57.0)	42.0**
Lei 2020 (76)	Wuhan	Case series	2020/01/10–2020/01/30	51	25 (49.0)	55.0**
Sun 2020 (77)	Henan	Case series	2020/01/24–2020/02/26	129	59 (45.7)	45.0**
Bai 2020 (78)	Shanxi	Case series	2020/01/01–2020/03/06	120	63 (52.5)	49.4±18.2*
Chen 2020 (79)	Jiangsu	Case series	2019/12/01–2020/03/01	30	17 (56.7)	48.9±13.1*
Zhong 2020 (80)	Hainan	Case series	2020/01/21–2020/02/10	62	40 (64.5)	51.8±13.5*
Zhu 2020 (81)	Anhui	Case series	2020/01/18–2020/03/08	79	44 (55.7)	56.1±12.7*
Li 2020 (45)	Hubei	Case series	2020/01/21–2020/03/02	193	112 (58.0)	50.7±16.2*
Zhang 2020 (82)	Anhui	Case series	2020/01/23–2020/02/15	36	20 (55.6)	(8,75)***
Zhang 2020 (83)	Wuhan	Case series	2020/01/19–2020/02/08	10	7 (70.0)	74.5**
Xia 2020 (84)	Wuhan	Case series	2020/01/15–2020/02/08	52	23 (44.2)	54.0±12.8*
Zheng 2020 (85)	Wuhan	Case series	2020/01/01–2020/02/01	71	35 (49.3)	62.0 (53.5, 70.0)**
Sun 2020 (86)	Wuhan	Case series	2020/02/09–2020/02/27	51	27 (52.9)	68.0*
Sun 2020 (87)	Henan	Case series	2020/01/24–2020/02/16	150	67 (44.7)	45.0±16.0*
Xu 2020 (54)	Zhejiang	Case series	2020/01/10–2020/01/26	62	35 (56.5)	41.0 (32.0, 52.0)**
Tian 2020 (88)	Hubei	Case series	2020/01/13–2020/02/13	25	11 (44.0)	38.0**
Chen 2020 (89)	Guangdong	Case series	2020/01/11–2020/02/02	12	8 (66.7)	63.0*
Yin 2020 (90)	Wuhan	Case series	2020/01/31–2020/02/10	95	34 (35.8)	35.0**
Yu 2020 (91)	Beijing	Case series	From 2020/01/21	40	26 (65.0)	39.9±18.2*
Cui 2020 (92)	Gansu	Case series	–	8	5 (62.5)	40.1*
Shang 2020 (93)	Anhui	Case series	2020/01/22–2020/02/19	36	21 (58.3)	38.6±10.6*
Hao 2020 (94)	Zhejiang	Case series	2020/01/17–2020/02/12	788	407 (51.6)	46.0 (35.0, 55.8)**

Table S1 (*continued*)

Table S1 (*continued*)

Study ID	Study location	Study type	Time	Sample size	Sex (%,man)	Age (year)
Wang 2020 (95)	Shandong	Case series	2020/01/31–2020/02/12	26	11 (42.3)	42.0 (34.0, 53.0)**
Tian 2020 (96)	Shandong	Case series	–	37	17 (45.9)	44.3±16.7*
Xu 2020 (37)	Zhejiang	Case series	2020/01/13–2020/02/19	113	66 (58.4)	52.0 (43.0, 63.0)**
Zhu 2020 (97)	Anhui	Case series	2020/01/24–2020/02/20	116	56 (48.3)	40.0 (27.0, 53.0)**
Huang 2020 (47)	Hunan	Case series	2020/01/17–2020/02/10	54	28 (51.9)	41.0 (31.0, 51.0)**
Jiang 2020 (48)	Zhejiang	Case series	2020/01/16–2020/01/31	60	35 (58.3)	41.0**
Xu 2020 (54)	Zhejiang	Case series	2020/01/10–2020/02/26	62	35 (56.5)	41.0 (32.0, 52.0)**
Huang 2020 (35)	Hubei	Case series	2020/01/25–2020/03/24	299	160 (53.5)	53.4±16.7*
Huang 2020 (2)	Wuhan	Case series	2019/12/16–2020/01/02	41	30 (73.2)	49.0 (41.0, 58.0)**
Lauer 2020 (98)	Outside of Hubei	Case series	2020/01/04–2020/02/24	181	108 (59.7)	44.5 (34.0, 55.5)**
Xie 2020 (99)	Shanghai	Case series	2020/01/01–2020/02/15	105	54 (51.4)	44.1±18.1*
Shi 2020 (100)	Shanghai	Case series	2020/01/20–2020/02/07	184	99 (53.8)	49.0±15.0*
Hu 2020 (32)	Shandong	Cohort study	2020/01/29–2020/03/12	59	28 (47.5)	46.0 (33.0, 57.0)**
Liang 2020 (34)	China	Cohort study	2019/11/21–2020/01/31	1590	904 (57.3)	48.9±16.3*
Deng 2020 (36)	Wuhan	Case series	2020/01/01–2020/02/21	225	124 (55.1)	–
Hua 2020 (101)	Wuhan	Case series	2020/02/07–2020/02/26	205	112 (54.6)	51.0 (39.0, 57.0)**
Lu 2020 (102)	Jiangsu	Case series	2020/01/23–2020/02/26	28	17 (60.7)	48.3±13.5*
Shen 2020 (103)	Shanghai	Case series	2020/01/20–2020/02/29	325	168 (51.7)	50.0*
Tian 2020 (42)	Beijing	Case series	2020/01/20–2020/02/10	262	127 (48.5)	47.5 (45.1, 49.9)**
Shi 2020 (104)	Wuhan	Case series	2020/01/20–2020/02/10	416	205 (49.3)	64.0 (21.0, 95.0)**
Hung 2020 (105)	Hongkong	Case series	2020/02/10–2020/03/20	127	68 (53.5)	52.0 (32.0, 62.0)**
Zhao 2020 (106)	Hubei	Case series	2020/01/16–2020/02/17	136	68 (50.0)	49.0 (33.0, 63.0)**
Qi 2020 (38)	Guangdong	Cohort study	2020/01/24–2020/03/08	147	80 (54.4)	42.0 (35.0, 54.0)**
Yu 2020 (107)	Wuhan	Case series	2020/02/13–2020/02/28	129	56 (43.4)	64.0 (56.0, 69.0)**
Zhou 2020 (39)	Wuhan	Cohort study	2020/01/15–2020/03/15	238	102 (42.9)	55.5 (35.0, 67.3)**
Xia 2020 (108)	Wuhan	Case series	2020/02/04–2020/03/30	1568	797 (50.8)	63.0 (55.0, 71.0)**
Miao 2020 (109)	Shanghai	Case series	2020/01/12–2020/02/13	54	28 (51.9)	45.1±13.4*
Huang 2020 (49)	Jiangsu	Case series	2020/01/22–2020/02/10	202	116 (57.4)	44.0 (33.0, 54.0)**
Lam 2020 (110)	Hongkong	Case series	2020/01/23–2020/05/31	1084	588 (54.2)	37.5*
Wang 2020 (111)	Wuhan	Case series	To 2020/02/10	107	57 (53.3)	51.0 (36.0, 65.0)**
Zeng 2020 (112)	Sichuan	Case series	2020/01/16–2020/02/05	20	12 (60)	57.4±16.5*
Zou 2020 (113)	Wuhan	Case series	2020/01/01–2020/01/29	15	10 (66.7)	61.7±9.6*
Ding 2020 (114)	Wuhan	Case series	2020/01/01–2020/02/03	56	30 (53.6)	54.6±15.5*
Li 2020 (115)	Henan	Case series	2020/01/20–2020/02/17	40	20 (50.0)	50.9*
Wu 2020 (30)	Hubei	Case series	2020/01/01–2020/03/22	102	75 (73.5)	51.6±19.3*
Wang 2020 (116)	Wuhan	Case series	2020/01/20–2020/02/14	96	46 (47.9)	–
Zhai 2020 (43)	Anhui	Case series	2020/01/22–2020/03/04	74	41 (55.4)	54.9±11.8*
Tian 2020 (117)	Jiangsu	Case series	2020/01/23–2020/02/16	23	10 (43.5)	49.7±13.1*
Yu 2020 (118)	Wuhan	Case series	2020/12/18–2020/01/29	608	398 (65.5)	60.2±8.7*
Tian 2020 (119)	Jiangsu	Case series	2020/01/23–2020/02/10	26	14 (53.9)	47.9±13.1*
Shang 2020 (120)	Anhui	Case series	2020/01/22–2020/02/19	36	21 (58.3)	38.6±10.6*
Zeng 2020 (121)	Hunan	Case series	2020/01/24–2020/02/19	79	41 (51.9)	45.9±12.7*
Hong 2020 (122)	Guangdong	Case series	2020/01/17–2020/03/01	18	9 (50.0)	63.5 (51.5, 67.5)**
Wang 2020 (123)	Wuhan	Case series	2020/01/10–2020/02/08	312	145 (46.5)	52.0 (42.0, 62.0)**
Lin 2020 (124)	Zhejiang	Case series	2020/01/15–2020/02/05	71	22 (31.0)	50.3±14.6*
Tu 2020 (125)	Wuhan	Case series	2020/01/10–2020/02/29	75	53 (70.7)	68.0 (62.0, 74.0)**
Liu 2020 (126)	Wuhan	Case series	2020/01/16–2020/02/15	64	23 (35.9)	35.0 (29.0, 43.0)**
Chen 2020 (127)	Guangdong	Case series	2020/01/20–2020/03/15	284	131 (46.1)	48.0 (33.0, 62.0)**
Chen 2020 (128)	Wuhan	Case series	2020/01/01–2020/03/02	30	14 (46.7)	60.5 (32.0, 77.0)**
Yao 2020 (129)	Wuhan	Case series	2020/01/26–2020/02/18	55	37 (67.3)	70.7±13.5*
Zhang 2020 (130)	Wuhan	Case series	2020/01/20–2020/02/29	564	286 (50.7)	60.0 (48.0, 67.0)**
Duan 2020 (131)	Wuhan	Case series	2020/01/01–2020/01/31	116	58 (50.0)	62.5 (55, 68.3)**
Leung 2020 (132)	Hongkong	Case series	2020/01/26–2020/02/28	50	23 (46.0)	55.2±19.5*

*, mean SD; **, median (IQR); ***, range; –, not report.

Table S2 Case series

Study ID	Item 1	Item 2	Item 3	Item 4	Item 5	Item 6	Item 7	Item 8	Scores[††]
Luo 2020 (11)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Ng 2020 (21)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Jung 2020 (22)	Yes	Yes	Yes	Yes	No	Yes	Yes	No	6
Hong 2020 (23)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Husain 2020 (24)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Dreher 2020 (26)	No	Yes	Yes	No	No	Yes	Yes	Yes	5
Imai 2020 (27)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Mahévas 2020 (28)	Yes	Yes	Yes	Yes	Yes	No	Yes	No	6
Gao 2020 (58)	Yes	Yes	Yes	Yes	No	Yes	Yes	No	6
Fu 2020 (59)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Liu 2020 (31)	No	Yes	No	Yes	No	Yes	Yes	Yes	5
Liu 2020 (60)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Huang 2020 (61)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Liu 2020 (40)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Liu 2020 (62)	No	No	No	Yes	No	Yes	Yes	No	3
Han 2020 (44)	Yes	Yes	No	No	No	No	Yes	No	3
Yu 2020 (63)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Xia 2020 (64)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Chen 2020 (41)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Ye 2020 (33)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Yang 2020 (65)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Li 2020 (66)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Cao 2020 (67)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Yuan 2020 (46)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Zeng 2020 (68)	Yes	Yes	No	Yes	No	Yes	Yes	No	5
Chen 2020 (69)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Hu 2020 (70)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Zhang 2020 (71)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Yang 2020 (72)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
An 2020 (73)	No	Yes	No	Yes	No	Yes	Yes	Yes	5
Liu 2020 (74)	No	Yes	No	Yes	No	Yes	Yes	No	4
Li 2020 (29)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Shi 2020 (75)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Lei 2020 (76)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Sun 2020 (77)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Bai 2020 (78)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Chen 2020 (79)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Zhong 2020 (80)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Zhu 2020 (81)	No	Yes	No	Yes	No	Yes	Yes	Yes	5
Li 2020 (45)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Zhang 2020 (82)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Zhang 2020 (83)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Xia 2020 (84)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Zheng 2020 (85)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Sun 2020 (86)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Sun 2020 (87)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Xu 2020 (54)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Tian 2020 (88)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Chen 2020 (89)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Yin 2020 (90)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Yu 2020 (91)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Cui 2020 (92)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Shang 2020 (93)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Hao 2020 (94)	Yes	No	Yes	Yes	No	Yes	Yes	Yes	6
Wang 2020 (95)	No	Yes	Yes	No	No	Yes	Yes	No	4
Tian 2020 (96)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6

Table S2 (*continued*)

Table S2 (*continued*)

Study ID	Item 1	Item 2	Item 3	Item 4	Item 5	Item 6	Item 7	Item 8	Scores[††]
Xu 2020 (37)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Zhu 2020 (97)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Huang 2020 (47)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Jiang 2020 (48)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Xu 2020 (54)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Huang 2020 (35)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Huang 2020 (2)	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	7
Lauer 2020 (98)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Xie 2020 (99)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Shi 2020 (100)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Deng 2020 (36)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Hua 2020 (101)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Lu 2020 (102)	No	No	Yes	Yes	No	Yes	Yes	No	4
Shen 2020 (103)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Tian 2020 (42)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Shi 2020 (104)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Hung 2020 (105)	Yes	Yes	Yes	No	No	Yes	Yes	Yes	6
Zhao 2020 (106)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Yu 2020 (107)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Xia 2020 (108)	No	Yes	No	Yes	No	Yes	Yes	Yes	5
Miao 2020 (109)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Huang 2020 (49)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Lam 2020 (110)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Wang 2020 (111)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7
Zeng 2020 (112)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Zou 2020 (113)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Ding 2020 (114)	No	Yes	No	Yes	No	Yes	Yes	No	4
Li 2020 (115)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Wu 2020 (30)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Wang 2020 (116)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Zhai 2020 (43)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Tian 2020 (117)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Yu 2020 (118)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Tian 2020 (119)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Shang 2020 (120)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Zeng 2020 (121)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Hong 2020 (122)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Wang 2020 (123)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Lin 2020 (124)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Tu 2020 (125)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Liu 2020 (126)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Chen 2020 (127)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Chen 2020 (128)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Yao 2020 (129)	No	Yes	Yes	Yes	No	Yes	Yes	No	5
Zhang 2020 (130)	Yes	No	Yes	Yes	No	Yes	Yes	Yes	6
Duan 2020 (131)	No	Yes	Yes	Yes	No	Yes	Yes	Yes	6
Leung 2020 (132)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	7

[††], according to the methodology evaluation tool recommended by National Institute for Health and Care Excellence. The risk of bias is evaluated according to eight criteria. The results were summarized by scoring method, for the "Yes" items, the score was 1, and for the "no" items, the score was 0. The maximum score is 8; the higher the score, the lower the risk of bias. The numbers 1 to 8 refer to the items of the tool: 1. case series collected in more than one centre, i.e., multi-centre study; 2. is the hypothesis/aim/objective of the study clearly described? 3. are the inclusion and exclusion criteria (case definition) clearly reported? 4. is there a clear definition of the outcomes reported? 5. were data collected prospectively? 6. is there an explicit statement that patients were recruited consecutively? 7. are the main findings of the study clearly described? 8. are outcomes stratified? (e.g., by disease stage, abnormal test results, patient characteristics).

Table S3 Cohort study

Study ID	Selection				Comparability		Exposure			Scores[†††]
	Item 1	Item 2	Item 3	Item 4	Item 5	Item 6	Item 7	Item 8	Item 9	
Young 2020 (20)	*	*	*	*	*	*	*	×	*	8
Cummings 2020 (25)	*	×	*	*	×	*	*	*	×	6
Hu 2020 (32)	*	×	*	×	×	*	*	×	×	4
Liang 2020 (34)	*	*	*	*	*	*	*	×	×	7
Qi 2020 (38)	*	*	*	×	*	*	*	×	×	6
Zhou 2020 (39)	*	*	*	×	*	*	*	×	×	6

[†††], according to the methodology evaluation tool of Newcastle-Ottawa Scale. It consists of eight domains, for each, we will grade with stars. The more stars, the lower the risk of bias. The maximum score is 9. A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability. The numbers 1 to 8 refer to the items of the tool: 1. representativeness of the exposed cohort; 2. selection of the non-exposed cohort; 3. ascertainment of exposure; 4. demonstration that outcome of interest was not present at start of study; 5. comparability of cohorts on the basis of the design; 6. comparability of cohorts on the basis of analysis; 7. assessment of outcome; 8. duration of follow-up; 9. adequacy of follow up of cohorts. *, adequate; ×, not adequate/unclear.

Table S4 Summary of findings

Outcomes	No.of studies	Sample size	Certainty assessment					MD (95% CI)	Certainty
			Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations		
Duration from symptom onset to first medical visit of the common patients and severe patients	6	1376	Serious[1]	Not serious	Not serious	Not serious	None	−1.25 (−1.71, −0.80)	⊕◯◯◯ very low
Duration from symptom onset to admission of the common patients and severe patients	7	1593	Serious[1]	Not serious	Not serious	Not serious	None	−1.92 (−2.55, −1.30)	⊕◯◯◯ very low

[1], downgrade one level: the risk of bias is high due to the limitations of study design. MD, mean difference; CI, confidence interval.

References

58. Gao T, Xu Y, He X, et al. Epidemiological and clinical characteristics of 40 patients with coronavirus disease 2019 outside Hubei. Chinese Journal of Respiratory and Critical Care Medicine 2020;19:148-53.

59. Fu G, Deng J, Xiang J, et al. Clinical characteristics and prognosis in 51 severe cases of COVID-2019. Journal of Chongqing Medical University 2020;45:948-55.

60. Liu X, Xu Y, Hu M, et al. Epidemiological and clinical characteristics of 47 corona virus disease 2019 non-survivors in Huoshenshan Hospital. Med J Chin PLA 2020;45:475-80.

61. Huang H, Xu L, Zhang L, et al. Analysis of the Clinical Characteristics of 305 Patients with COVID-19 in Jinyintan Hospital of Wuhan City at Different Stage of the Epidemic. Herald of Medicine 2020;39:797-802.

62. Liu J, Chen C, Xia S. Clinical characteristics of 15 40 patients with coronavirus disease 2019. Henan Journal of Preventive Medicine 2020;31:161-4.

63. Yu S, Cui Y, Wang Z, et al. Traditional Chinese Medicine Syndrome Analysis of Patients with Coronavirus Disease 2019 on Admission. World Chinese Medicine 2020;31:161-4.

64. Xia Y, Zou Q, Dai S, et al. Epidemiological and clinical characteristics of 33 cases of new coronavirus pneumonia in ChangSha area. Journal of Pratical Shock 2020;4:88-91.

65. Yang K, Ren M, Xiao L, et al. Epidemiological and clinical characteristics of 57 cases of new coronavirus pneumonia in non-epidemic areas. Journal of Third Military Medical University 1-5[2020-12-04].

66. Li C, Ma Q, Ying H, et al. Epidemiological features and prevention measures of COVID-19 in high incidence areas of Henan Province. Medical Journal of Wuhan University 2020;41:521-8.

67. Cao P, Li X, Yan X, et al. Retrospective epidemiological analysis of 223 patients of COVID-19 in Chongqing. Journal of Southwest University (Natural Science Edition) 2020;42:10-6.

68. Zeng X, Yu W, Sun X, et al. Analysis on COVID-19 Confirmed Patients' Activity Trajectory in Chongqing. Medicine and Jurisprudence 2020;12:43-5.

69. Chen W, Lin J, Wu S, et al. Epidemiological characteristics and infection risk factors of people with close contact with coronavirus disease 2019 patients in Fujian Province. Chin J Dis Control Prev 2020;24:562-6, 585.

70. Hu S, Xu Q, Luo K, et al. Epidemiological characteristics of patients with coronavirus disease 2019 in Hunan province. Pract Prev Med 2020;27:385-8.

71. Zhang Y, Lei L, Xu Y, et al. Clinical Efficacy of Jinyinhua Oral Liquid in the Treatment of 80 Patients with Coronavirus Disease 2019. China Pharmaceuticals 2020;29:23-6.

72. Yang MW, Chen F, Zhu DJ, et al. Clinical efficacy of Matrine and Sodium Chloride Injection in treatment of 40 cases of COVID-19. Zhongguo Zhong Yao Za Zhi 2020;45:2221-31.

73. An W, Xia F, Chen M, et al. Clinical features of 11 deaths cases with COVID-19. The Journal of Practical Medicine 2020;36:1125-30.

74. Liu H, Zheng S, Chen J, et al. Analysis of EpidemioLogical Characteristics of New Coronavirus Pneumonia in Shaanxi Province and Thoughts on Prevention and Treatment of Traditional Chinese Medicine 2020;43:6-13.

75. Shi J, Ning H, Liu S, et al. Analysis of clinical and epidemiological characteristics of 65 cases of COVID-19 in Wenzhou. Journal of New Medicine 2020;51:360-4.

76. Lei Y, Lu J, Gu J, et al. Clinical features of 51 patients with corona virus disease 2019 in Wuhan City. Journal of Shandong University (Health sciences). 1-62020-12-04. Available online: http://kns.cnki.net/kcms/detail/37.1390.R.20200414.1315.006.html

77. Sun C, Liu P, Cui Y, et al. Comparative study on epidemiology and clinical characteristic in patients with imported and local secondary COVID-19. Journal of Chongqing Medical University 2020;45:962-7.

78. Bai Y, Ji Z, Zhang H, et al. Analysis on the epidemiological characteristics of an outbreak of coronavirus disease 2019(COVID-19) in Xi'an. Chin J Dis Control Prev 2020;24:567-72.

79. Chen Y, Zhang T. Clinical features and CT imaging findings of patients with corona virus disease-19. CT Theory and Applications 2020;29:155-62.

80. Zhong S, Lin F, Shi L. Clinical characteristics and outcomes of the patients with COVID-19: A report of 62 cases. Med J Chin PLA 2020;45:370-4.

81. Zhu L, Guo F, Wang L. Analysis of clinical and imaging features of elderly patients with COVID-19 elderly patients. Journal of Gannan Medical University 2020;40:341-6.

82. Zhang N, Chen F, Li N. The clinical value of chest CT in the diagnosis of COVID-19. Journal of Shenyang Medical College 2020;22:206-9.

83. Zhang N, Xu X, Li Y, et al. Application of chest CT in diagnosis and treatment of COVID-19 patients. Journal of Cardiovascular & Pulmonary Diseases 2020;39:127-33.

84. Xia W, An C, Zheng C, et al. A clinical study of 34 patients of COVID-19 treated with Integrated Chinese and Western medicine. Journal of Traditional Chinese Medicine 2020;61:375-82.

85. Zheng K, Ning F, Xu Y, et al. Risk factors affecting the early treatment effect of patients with severe coronavirus disease 2019. Academic Journal of Second Military Medical University 2020;41:371-7.

86. Sun D, Zhang D, Tian R, et al. Influencing factors and clinical significance of liver function damage in patients diagnosed with COVID-19. Chin J Dig Surg 12020:360-5.

87. Sun C, Zhang XB, Dai Y, et al. Clinical analysis of 150 cases of 2019 novel coronavirus infection in Nanyang City, Henan Province. Zhonghua Jie He He Hu Xi Za Zhi 2020;43:503-8.

88. Tian K, Liu T, Yao M, et al. An event of COVI D-19 in hospital colleagues and family members. Chinese Journal of Infection Control 2020;19:696-700.

89. Chen L, Feng S, Wang F, et al. Clinical diagnosis and treatment of critical patients with novel coronavirus pneumonia. Chinese Journal of Clinical Medicine 2020;27:32-5.

90. Yin J, Li R, Wu X. Clinical characteristics of COVID-19 among hospital staff. Medical Journal of Wuhan University. doi: 10.14188/j.1671-8852.2020.0427.

91. Yu S, Cui Y, Wang Z, et al. Analysis of the relationship between clinical features and tongue manifestations of 40 cases with corona virus disease 2019. Beijing Journal of Traditional Chinese Medicine 2020;39:111-4.

92. Cui X, Li J, Mao X, et al. Clinical characteristics of Corona Virus Disease 2019 before and after treatment: a single-center retrospective study. Journal of Lanzhou University (Medical Sciences) 2020;46:55-61.

93. Shang X, Liu H, Zhu L, et al. Epidemiological and clinical characteristics coronavirus disease 2019: a report of 36 cases. Chin J Diffic and Compl Cas 2020;19:563-5, 573.

94. Hao SR, Zhang SY, Lian JS, et al. Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study. Am J Gastroenterol 2020;115:1075-83.

95. Wang L, Duan Y, Zhang W, et al. Epidemiologic and Clinical Characteristics of 26 Cases of COVID-19 Arising from Patient-to-Patient Transmission in Liaocheng, China. Clin Epidemiol 2020;12:387-91.

96. Tian S, Chang Z, Wang Y, et al. Clinical Characteristics and Reasons for Differences in Duration From Symptom Onset to Release From Quarantine Among Patients With COVID-19 in Liaocheng, China. Front Med (Lausanne) 2020;7:210.

97. Zhu W, Xie K, Lu H, et al. Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China. J Med Virol 2020;92:1525-32.

98. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 2020;172:577-82.

99. Xie S, Zhang G, Yu H, et al. The epidemiologic and clinical features of suspected and confirmed cases of imported 2019 novel coronavirus pneumonia in north Shanghai, China. Ann Transl Med 2020;8:637.

100. Shi X, Lu Y, Li R, et al. Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia in Shanghai, China. J Med Virol 2020;92:1922-31.

101. Hua J, Chen R, Zhao L, et al. Epidemiological features and medical care-seeking process of patients with COVID-19 in Wuhan, China. ERJ Open Res 2020.

102. Lu R, Qin J, Wu Y, et al. Epidemiological and clinical characteristics of COVID-19 patients in Nantong, China. J Infect Dev Ctries 2020;14:440-6.

103. Shen Y, Zheng F, Sun D, et al. Epidemiology and clinical course of COVID-19 in Shanghai, China. Emerg Microbes Infect 2020;9:1537-45.

104. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:802-10.

105. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395:1695-704.

106. Zhao C, Xu Y, Zhang X, et al. Public health initiatives from hospitalized patients with COVID-19, China. J Infect Public Health 2020;13:1229-36.

107. Yu T, Tian C, Chu S, et al. COVID-19 patients benefit from early antiviral treatment: A comparative, retrospective study. J Med Virol 2020;92:2675-83.

108. Xia X, Li K, Wu L, et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood 2020;136:755-9.

109. Miao C, Jin M, Miao L, et al. Early chest computed tomography to diagnose COVID-19 from suspected patients: A multicenter retrospective study. Am J Emerg Med 2021;44:346-51.

110. Lam HY, Lam TS, Wong CH, et al. The epidemiology of COVID-19 cases and the successful containment strategy in Hong Kong-January to May 2020. Int J Infect Dis 2020;98:51-8.

111. Wang D, Yin Y, Hu C, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit Care 2020;24:188.

112. Zeng M, Lei X, Hang M, et al. Epidemiological and clinical characteristics of 20 severe cases of coronavirus disease 2019 in Sichuan Province. West Chin Med J 2020;35:377-84.

113. Li B, Xu Y, Feng M, et al. Clinical features of COVID-19 in 40 patients. Henan J Prev Med 2020;31:404-5, 435.

114. Wang R, Xie L, Du P, et al. Clinical characteristics of 96 hospitalized patients with coronavirus disease 2019. Chinese Journal of Respiratory and Critical Care Medicine 2020;19:144-7.

115. Tian J, Dong Y, Xu C, et al. Epidemic characteristics of COVID-19 cases in Yangzhou. Prev Med 2020;32:489-91.

116. Yu C, Li X, Wang L, et al. Retrospective analysis of 608 cases of COVID-19 in outpatient and emergency department. Journal of Traditional Chinese Medicine 2020;61:1570-2.
117. Tian L, Xu J, Li H, et al. Clinical characteristics of 26 cases of 2019 novel coronavirus-infected pneumonia. Journal of Nantong University (Medical Sciences) 2020;40:99-102.
118. Shang X, Liu H, Zhu L, et al. Epidemiological and clinical characteristics of patients with coronavirus disease 2019 in FuYang city, AnHui province. Chinese Journal of Difficult and Complicated Cases. 1-52020-12-05.
119. Zeng X, Xie Z, Xie Y, et al. Epidemiology of 79 confirmed COVID-19 cases and their nucleic acid test results in Changde city. Pract Prev Med 2020;27:524-6.
120. Hong Z, Zheng X, Yang X, et al. Comparative analysis of the clinical characteristics of 18 severe /critical coronavirus disease 2019 patients with myocardial injury. Chin J Arterioscler 2020;28:290-5.
121. Wang T, Hu X, Li L, et al. Analysis of Clinical Characteristics of 312 Cases of Patients with Coronavirus Disease 2019 in Fever Clinic. Herald of Medicine 2020;39:790-6.
122. Lin J, Yan K, Dai Q, et al. Retrospective study and thinking on prevention and control strategy base on COVID-19 cases in Ningbo city. Modern Practical Medicine 2020;27:524-6.
123. Tu Y, Yang P, Zhou Y, et al. Potential Predictors for Early Invasive Ventilation in Critically Ill Patients with COVID-19 in Wuhan, China: A Single-Centered, Retrospective, Observational Study. Social ence Electronic Publishing.
124. Liu J, Ouyang L, Fu P, et al. Epidemiological, Clinical, Radiological Characteristics and Outcomes of Medical Staff with COVID-19 in Wuhan, China: A Single-Centered, Retrospective Case Series Analysis. Social ence Electronic Publishing.
125. Chen X, Zhu B, Hong W, et al. Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. Int J Infect Dis 2020;98:252-60.
126. Chen X, Yuan W, Shao Z, et al. The Desynchrony between Clinical Course and RT-PCR Test Resultsin Patientswith COVID-19 Infected Pneumonia During the Treatment in Wuhan, China. Social Science Electronic Publishing.
127. Yao T, Gao Y, Cui Q, et al. Clinical Characteristics of 55 Cases of Deaths with COVID-19 Pneumonia in Wuhan, China: Retrospective Case Series. Social ence Electronic Publishing.
128. Zhang L, Bai T, Jin Y, et al. Diarrhea in Patients with Coronavirus Disease 2019: Clinical Characteristics, Outcomes and Implications. SSRN Electronic Journal 2020.
129. Duan Q, Guo G, Ren Y, et al. Treatment Outcomes, Influence Factors of 116 Hospitalized COVID-19 Patients with Longer/Prolonged Treatment Course in Wuhan, China. Social ence Electronic Publishing.
130. Leung SS, Ng TL, Wu KL, et al. A Territory-Wide Study of COVID-19 Cases and Clusters with Unknown Source in Hong Kong Community: A Clinical, Epidemiological and Phylogenomic Investigation. Social ence Electronic Publishing.
131. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606.
132. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.